As the U.S. markets navigate a period of retreat from record highs, particularly with tech stocks experiencing notable declines, investors are closely monitoring key economic indicators such as inflation and Federal Reserve policies that could impact future market performance. In this context of fluctuating indices and evolving economic conditions, identifying high growth tech stocks involves assessing companies with robust innovation capabilities, strong revenue potential in emerging technologies like AI, and resilience to broader market volatility.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| ACADIA Pharmaceuticals | 10.87% | 25.66% | ★★★★★☆ |
| ADMA Biologics | 20.60% | 23.25% | ★★★★★☆ |
| Palantir Technologies | 25.17% | 31.57% | ★★★★★★ |
| Workday | 11.51% | 29.07% | ★★★★★☆ |
| OS Therapies | 57.14% | 70.11% | ★★★★★☆ |
| Circle Internet Group | 27.36% | 77.54% | ★★★★★☆ |
| RenovoRx | 65.52% | 68.63% | ★★★★★☆ |
| Gorilla Technology Group | 27.68% | 129.58% | ★★★★★☆ |
| Vanda Pharmaceuticals | 22.66% | 59.11% | ★★★★★☆ |
| Monopar Therapeutics | 76.01% | 54.38% | ★★★★★☆ |
Click here to see the full list of 71 stocks from our US High Growth Tech and AI Stocks screener.
Let's dive into some prime choices out of from the screener.
Gorilla Technology Group (GRRR)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Gorilla Technology Group Inc. is a company that offers security, network, business intelligence, and IoT technology solutions in Taiwan and the United Kingdom, with a market capitalization of approximately $474.47 million.
Operations: Gorilla Technology Group Inc. generates revenue primarily through its Security Convergence segment, which accounts for $143.32 million, and its Video IoT segment at $3.54 million. The company operates in Taiwan and the United Kingdom, focusing on security and IoT technology solutions.
Gorilla Technology Group, despite recent financial turbulence with a reported net loss of USD 8.5 million for the first half of 2025, remains optimistic about its future, projecting annual revenues to reach between $100 million and $110 million. This confidence is underpinned by a robust annualized revenue growth rate of 27.7% and an impressive forecasted earnings growth of 129.6%. The firm's commitment to innovation is evident from its significant R&D spending, which not only fuels its AI-based Industrial IoT and Security Convergence technologies but also positions it as a forward-thinking player in tech development.
Arcturus Therapeutics Holdings (ARCT)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Arcturus Therapeutics Holdings Inc. focuses on developing vaccines for infectious diseases and products for liver and respiratory rare diseases, with a market capitalization of $461.90 million.
Operations: Arcturus Therapeutics generates revenue primarily from the discovery, development, and commercialization of messenger RNA medicines, totaling $122.12 million. The company is involved in creating vaccines for infectious diseases and treatments for liver and respiratory rare diseases.
Arcturus Therapeutics Holdings, amid recent leadership changes and presenting at notable biotechnology conferences, reported a significant reduction in net loss to USD 9.18 million for Q2 2025 from USD 17.22 million year-over-year. This improvement aligns with their strategic focus on mRNA therapeutics, particularly ARCT-810 for OTC deficiency—a treatment showing promising Phase 2 results. Despite a revenue dip to USD 57.68 million over six months, the company's robust R&D efforts underscore its commitment to addressing rare metabolic disorders, positioning it as an innovator in genetic medicine with potential for future growth.
- Click to explore a detailed breakdown of our findings in Arcturus Therapeutics Holdings' health report.
Understand Arcturus Therapeutics Holdings' track record by examining our Past report.
National CineMedia (NCMI)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: National CineMedia, Inc. operates a cinema advertising network in North America through its subsidiary, National CineMedia, LLC, with a market cap of $411.39 million.
Operations: The company generates revenue primarily from advertising, totaling $235.30 million.
Despite National CineMedia's current unprofitability, its forward-looking indicators suggest potential for significant growth. With an expected revenue increase of 10.4% annually, NCMI is pacing ahead of the U.S. market average of 9.3%. Moreover, the company's earnings are projected to surge by an impressive 106.45% per year, signaling a robust turnaround from recent losses. This optimism is further bolstered by strategic moves like their partnership with Vistar Media to expand programmatic advertising capabilities—an innovation that has already accelerated revenue streams in this segment and could redefine engagement in cinema advertising landscapes.
Where To Now?
- Unlock more gems! Our US High Growth Tech and AI Stocks screener has unearthed 68 more companies for you to explore.Click here to unveil our expertly curated list of 71 US High Growth Tech and AI Stocks.
- Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
- Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.
Ready To Venture Into Other Investment Styles?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Arcturus Therapeutics Holdings might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com